Jaime L. Rudd; California Department of Fish and Wildilfe; 1701 Nimbus Road, Suite D CDFW - WIL, Rancho Cordova, CA, 95670; (916) 358-2378;; Stella C. McMillin, Mark W. Kenyon Jr. , Robert H. Poppenga, Deana L. Clifford, Deana L. Clifford
As part of a statewide mountain lion (Puma concolor) health study initiated in 2016 we determined the prevalence and geographic distribution of non-target anticoagulant rodenticide exposure in necropsied mountain lions. We used liquid chromatography/mass spectroscopy to detect rodenticides in liver samples from 111 (77 male: 34 female) mountain lion carcasses from 37 counties collected between February 2016 and 2017. Anticoagulant rodenticides (ARs) were detected in 105 of 111 (94.5%) lions sampled from 35 counties. First generation ARs (FGARs) were detected in 81 individuals (73%) from 33 counties and second generation ARs (SGARs) were detected in 102 individuals (92%) from 35 counties. Seventy-eight individuals (70%) were exposed to both SGARs and FGARs. Diphacinone was the most common FGAR, detected in 67% of sampled individuals. Brodifacoum was the most common SGAR, detected in 90% of sampled individuals. Exposure to ARs was not associated with lower body condition. Although only one year of data, we demonstrate that exposure to ARs is widespread in California's mountain lions. We recommend continued AR testing screening of mountain lion carcasses to monitor population health and measure the effectiveness of regulatory changes intended to reduce non-target wildlife exposure to rodenticides.
Ecology and Conservation of Mammals I